BC Partners, a international private equity firm, agreed to acquire a majority stake in Synthon International, a developer of complex Generics, from Synthon, a international science-centred pharmaceutical company focused on the provision of affordable, high-quality small-molecule generics and hybrids. Financial terms were not disclosed. BC Partners, in partnership with the founder, intends to build on this strong performance by investing in the expansion of Synthon’s product portfolio as well as its product pipeline and entering into new markets, which will allow Synthon to leverage its proven track record of commercialising complex pharmaceutical technologies. “We are privileged to be partnering with Jacques and backing a company with as high-quality a management team and operations as Synthon. The company has an exciting future ahead of it and we look forward to supporting Synthon as it continues to prosper,” Mark Hersee, BC Partners Partner.